

Research Concept: Bisphenol AF

Matthew D. Stout, Ph.D.

NIEHS/NTP

NTP Board of Scientific Counselors Meeting

November 20-21, 2008





Nomination

- Numerous toxicological effects have been associated with bisphenol A (BPA) in mammals, depending upon the level of exposure
 - Effects on reproduction and development and other endocrine-related biological effects
- NTP CERHR Brief on BPA
 - Some concern for effects on the brain, behavior, and prostate gland in fetuses, infants, and children at current human exposures
- Bisphenol AF (BPAF) was nominated following an NTP review of BPA-related chemicals, based on:
 - Moderate production and use as a monomer for polyimides, polyamides, polyesters, polycarbonates, and other specialty polymers
 - Estrogenic activity
 - Lack of adequate toxicity data



Production, Use and Human Exposure

- US annual production 10,000 500,000 pounds
- NIOSH National Occupational Exposure Survey (1981-1983)
 - Estimated 4388 employees (1460 females) potentially exposed
- Use information is very limited
 - Monomer in polycarbonates and epoxy resins, and possibly in food-contact polymers
- Predicted to be persistent in the environment
 - Presence of six fluorine atoms in the molecule
- Found in extracts of human female adipose tissue
- Production and use patterns suggest that human exposure to BPAF is much lower than to BPA



Endocrine Activities of Bisphenol AF

- It appears that BPAF has greater estrogenic activity than BPA, based on:
 - In vitro reporter gene assay
 - Uterotrophic assay
- BPAF may have other endocrine activities, including:
 - Anti-androgenic
 - In vitro reporter gene assay
 - Not confirmed by Hershberger assay
 - Anti-estrogenic effects inhibition of estrogenic effects upon co-exposure with potent estrogens
 - In vitro vitellogenin production
 - Uterotrophic assay
- BPAF binds ERRy
 - Binding affinity much less than with BPA
- The uterotrophic and Hershberger assays are the only in vivo studies reported in the literature for BPAF
 - No other information available to characterize toxicity



Key Issues

- Does BPAF have toxicity similar to that of other synthetic estrogens?
- Do structure-activity relationships exist among the compounds belonging to the class of BPA-related compounds?
 - The NTP is currently considering class approaches for evaluating the toxicity of BPA-related compounds



Proposed Approach

- Overall goal: to better understand the toxicology of BPAF
- Hypothesis: Observed toxicities will be characteristic of a synthetic estrogen
- Key components:
 - Exposures
 - Route oral
 - Inclusion of gestational and lactational periods
 - Wide spacing of doses
 - Disposition studies
 - Endpoints to characterize endocrine-related toxicities



Proposed Approach

- Tiered approach to research program:
 - Tier one study
 - Initial toxicological characterization
 - Tier two studies
 - Follow-up studies
 - Will be considered following review of toxicity data and future data on production, use, and exposure



Specific Aims

Tier one

Specific Aim 1: Conduct a transgenerational assay

- Rats exposed to a wide range of doses from gestation → sexual maturity (GD 6 → ~PND 100)
- Inclusion of both standard toxicity endpoints and sensitive endpoints to detect endocrine-related phenotypic effects
 - Onset of puberty in males and females
 - Uterine weight
 - Development of mammary tissue
- Analysis of disposition
- This study will characterize the toxicity of BPAF with emphasis on endocrine-related effects

Tier two

- Specific Aim 2: Conduct absorption, distribution, metabolism and elimination studies and toxicokinetic studies
- · Studies aimed at characterizing:
 - Changes in the metabolism of BPAF with life stage
 - Persistence of BPAF
- Specific Aim 3: Conduct multigenerational reproductive toxicity and developmental toxicity studies
- Additional endpoints may be included based on:
 - The results of the tier one study
 - Reported endocrine activities of BPAF
 - Reported effects of BPA



Significance and Expected Outcomes

- Identify hazards associated with exposure to BPAF
- Provide data on the potential for BPAF to induce toxicity consistent with that of a synthetic estrogen